High-alcohol medicinal formulations now need licence, prescription: Centre
Synopsis
The Centre has quietly closed a regulatory loophole that allowed aromatic tinctures with up to 90% alcohol to be sold without a licence or prescription. By pulling these products under Schedule H1 and stripping their Schedule K exemption, the government has acted on state-level warnings about misuse — a shift that will ripple through both the pharmaceutical supply chain and the grey market for cheap intoxicants.
Key Takeaways
The Centre notified amendments on 10 July ending Schedule K exemptions for high-alcohol medicinal formulations.
Products with more than 12 per cent v/v ethyl alcohol in packs exceeding 30 mL now require a manufacturer and seller licence under the Drugs and Cosmetics Act, 1940 .
Affected formulations — including tinctures of cardamom and ginger — can contain alcohol concentrations as high as 80–90 per cent v/v .
These products are now listed under Schedule H1 of the Drugs Rules, 1945 , requiring a registered medical practitioner's prescription for sale.
The move follows representations from state governments over documented misuse of these formulations for intoxication.
The Centre on Friday, 10 July tightened regulations governing medicinal formulations containing high concentrations of ethyl alcohol, mandating licensing requirements and prescription-only sale for such products. The move, notified through a Gazette notification issued by the Ministry of Health and Family Welfare, aims to curb misuse while preserving access for patients with legitimate therapeutic needs.
What Changed and Why
Several medicinal preparations — including tinctures of cardamom, ginger, and other aromatic formulations — were previously exempt from licensing requirements under Schedule K of the Drugs and Cosmetics Act, 1940. However, some of these products contain ethyl alcohol in concentrations as high as 80–90 per cent v/v, making them susceptible to misuse for intoxication. The Centre noted it had received representations from multiple state governments flagging concerns over exactly this kind of diversion.
The New Regulatory Threshold
Under the amended framework, all medicinal formulations containing more than 12 per cent v/v ethyl alcohol and packaged in quantities exceeding 30 mL will no longer qualify for exemption under Schedule K. Manufacturers and sellers of such products must now obtain the necessary licences under the Drugs and Cosmetics Act, 1940. Additionally, these formulations have been brought under Schedule H1 of the Drugs Rules, 1945 — a stricter tier of regulatory control that requires sale only against the prescription of a registered medical practitioner and mandates enhanced record-keeping.
Impact on Supply Chain and Public Health
According to the ministry, the revised framework is designed to ensure that high-alcohol medicinal products are supplied exclusively through the regulated pharmaceutical distribution chain. Officials said the change would significantly reduce the risk of diversion while maintaining continued access for patients requiring these medicines for genuine therapeutic purposes. Notably, the amendment is part of the government's broader push to strengthen India's drug regulatory architecture and promote rational use of medicinal products.
What Happens Next
The amendments have already been formally notified via the Gazette, meaning they carry immediate legal force. Manufacturers and distributors of affected formulations will need to align their operations with the new licensing and prescription requirements. Compliance timelines and enforcement modalities are expected to be communicated through state drug regulatory authorities. This regulatory tightening reflects a growing pattern of Centre-state coordination on drug misuse — a trend that has accelerated over the past two years as states flagged abuse of Schedule K-exempt products.
Point of View
Widely available remedies — not for products that are, in effect, near-pure alcohol in medicinal packaging. The fact that state governments had to escalate the issue suggests that central drug regulators were slow to act on a known misuse vector. The shift to Schedule H1 is the right call, but enforcement is where such reforms typically stall in India: without robust point-of-sale checks and pharmacist accountability, a prescription requirement alone may not be sufficient to deter determined misuse.
NationPress
10 Jul 2026
Frequently Asked Questions
What formulations are now required to have a licence and prescription in India?
Medicinal formulations containing more than 12 per cent v/v ethyl alcohol and packaged in quantities exceeding 30 mL are now subject to licensing requirements and can only be sold against a registered medical practitioner's prescription. This includes aromatic tinctures such as those of cardamom and ginger, which were previously exempt under Schedule K of the Drugs and Cosmetics Act, 1940.
Why did the Centre tighten rules on alcohol-containing medicinal formulations?
Several Schedule K-exempt products were found to contain ethyl alcohol concentrations of up to 80–90 per cent v/v, making them vulnerable to misuse as cheap intoxicants. The Centre acted after receiving formal representations from state governments flagging documented cases of such misuse.
What is Schedule H1 and what does it mean for these products?
Schedule H1 is a stricter regulatory category under the Drugs Rules, 1945 that permits sale only against a prescription from a registered medical practitioner and requires enhanced record-keeping by pharmacists. Placing high-alcohol formulations under Schedule H1 means they can no longer be sold over the counter.
When does this regulatory change take effect?
The amendments have been formally notified through a Gazette notification issued by the Ministry of Health and Family Welfare, giving them immediate legal force as of 10 July. Manufacturers and distributors are expected to receive compliance guidance from state drug regulatory authorities.
Will patients who need these medicines for legitimate purposes still be able to access them?
Yes. The ministry has clarified that the revised framework is designed to ensure continued access for patients with genuine therapeutic needs, while restricting supply to the regulated pharmaceutical distribution chain to prevent diversion.
